Dangos 1 - 7 canlyniadau o 7 ar gyfer chwilio 'Andrew Freywald (14851181)', amser ymholiad: 0.01e Mireinio'r Canlyniadau
  1. 1
    Supplementary Table S4 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

    Supplementary Table S4 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy gan Amr El Zawily (14851115)

    Cyhoeddwyd 2025
    Awduron Eraill:
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  2. 2
    Supplementary Table S7 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

    Supplementary Table S7 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy gan Amr El Zawily (14851115)

    Cyhoeddwyd 2025
    Awduron Eraill:
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  3. 3
    Supplementary Table S5 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

    Supplementary Table S5 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy gan Amr El Zawily (14851115)

    Cyhoeddwyd 2025
    Awduron Eraill:
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  4. 4
    Supplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

    Supplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy gan Amr El Zawily (14851115)

    Cyhoeddwyd 2025
    Awduron Eraill:
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  5. 5
    Supplementary Table S6 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

    Supplementary Table S6 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy gan Amr El Zawily (14851115)

    Cyhoeddwyd 2025
    Awduron Eraill:
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  6. 6
    Supplementary Table S1 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

    Supplementary Table S1 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy gan Amr El Zawily (14851115)

    Cyhoeddwyd 2025
    Awduron Eraill:
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  7. 7
    Supplementary Table S2 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

    Supplementary Table S2 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy gan Amr El Zawily (14851115)

    Cyhoeddwyd 2025
    Awduron Eraill:
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:

Offerynnau Chwilio: